Start here if you're new
what it is
BioNTech uses mRNA and other immune-system tools to make vaccines and cancer drugs, with COVID shots still paying most of the bills.
how it gets paid
Last year Bntx made $2.7B in revenue. COVID-19 vaccine revenue was the main engine at $2.9B, or 100% of sales.
what just happened
BioNTech posted EPS of -$0.14 versus a -$1.00 estimate, an 86% surprise, but the bigger issue is still replacing COVID revenue.
At a glance
B balance sheet — gets the job done, barely
5/100 earnings predictability — expect surprises
6.5% return on capital — nothing to write home about
xvary composite: 30/100 — weak
$3B fy2029 rev est
What they do
BioNTech uses mRNA and other immune-system tools to make vaccines and cancer drugs, with COVID shots still paying most of the bills.
Drug development usually burns cash for years. BioNTech already built a commercial machine that produced a 31.8% net profit margin and carries just $221 million of long-term debt, or 1% of capital. Translation: mRNA platform → reusable drug design system → your upside is multiple shots on goal without a balance sheet begging for mercy.
How they make money
$2.7B
annual revenue
COVID-19 vaccine revenue
$2.9B
Oncology product revenue
$0.0B
Infectious disease pipeline revenue
$0.0B
Other immunotherapy revenue
$0.0B
The products that matter
commercial vaccine revenue base
covid vaccine business
$37B in 2022 → $2.7B revenue now
this is still the only proven commercial engine in the numbers. the problem is obvious: the engine got dramatically smaller.
revenue reset
pre-commercial oncology platform
mRNA oncology pipeline
$26B market cap depends on it
the market is valuing future cancer drugs before they show up in the revenue line. in human-speak: this is where the upside is supposed to come from.
future bet
balance-sheet runway
cash position
$17.5B cash · $221M debt
cash is not a product, but here it functions like one. it funds the transition while the company tries to build a second act.
time buyer
Key numbers
31.8%
net margin
Net margin → profit after all costs → so what: even with sales normalizing, BioNTech still converts nearly 32 cents of every dollar into profit.
$221M
long-term debt
Long-term debt → money owed over years → so what: with debt equal to 1% of capital, the balance sheet is barely carrying a backpack.
6.5%
return on capital
Return on capital → profit generated from invested money → so what: the business is profitable, but not yet earning blockbuster returns from its asset base.
$93
18-month target
This published target sits about 12% below the $105.87 share price, which tells you the near-term setup is weaker than the long-term dream.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 4 — safer than 20% of stocks
- price stability 15 / 100
- long-term debt $221M (1% of capital)
- net profit margin 31.8% — keeps 32 cents of every dollar in revenue
- return on equity 6% — $0.06 profit for every $1 investors have put in
B — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in BNTX 3 years ago → it's now worth $7,400.
The index would have given you $13,880.
source: institutional data · total return
What just happened
beat estimates
BioNTech posted EPS of -$0.14 versus a -$1.00 estimate, an 86% surprise, but the bigger issue is still replacing COVID revenue.
The beat matters because expectations were low, not because the revenue mix is fixed. Trailing revenue is still $2.9 billion, while investor focus has shifted to when oncology can start contributing real sales.
$850M
ttm revenue
$0.14
eps
31.8%
net margin
the number that mattered
The 86% EPS surprise matters because it shows BioNTech is still outperforming depressed expectations, even as the market waits for a post-COVID revenue handoff.
-
this year is gearing up to be a datarich one for biontech.the biotechnology developer intends to release late-stage clinical data from seven oncology-based studies (more details below). also, some investments have been allotted to initiate roughly 15 new clinical trials by the end of 2026.
-
these developments have perhaps contributed to elevated investor sentiment.
-
to wit, these adrs have increased roughly 10% in value since our late-november report.
-
ongoing stock-price volatility is likely, as highlighted by the adrs’ wide 52-week trading range.the release of fourth-quarter and full-year 2025 earnings (shortly after this issue is published), may evoke further reactions from the investment community. our near-term estimates anticipate modest revenue growth over this year and next, as well as narrower share deficits.
-
the company’s pipeline is commendable.biontech’s research focus is centered around the high-growth oncology arena, and, to a lesser degree, infectious diseases.
source: yahoo finance consensus and company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk is the oncology pipeline failing to replace collapsed COVID-era revenue.
med
the revenue hole is already real
Revenue went from $37B in 2022 to $2.7B. That is not a slowdown. That is an entirely different company profile.
If new products do not emerge, the market keeps valuing promise instead of proof.
med
mRNA patent litigation can linger
A patent lawsuit tied to COVID-19 mRNA vaccine technology stayed in recent coverage. For BioNTech, platform credibility is part of the equity story, so legal overhang matters beyond one headline.
This risk does not need to kill the business to pressure sentiment. It only needs to cloud the economics of the remaining commercial franchise.
med
the stock trades like uncertainty
Price stability is 15/100, and the stock has badly trailed the market over the last three years. That means even good science may not translate into smooth returns for you.
When fundamentals are thin, sentiment becomes a bigger driver than most investors want to admit.
med
institutions still want more proof
Institutions have been net sellers for three straight quarters, including 102 buyers versus 118 sellers in 3q2025. That is not capitulation. It is hesitation.
If professional holders are trimming while revenue stays stuck near $2.7B, multiple expansion gets harder.
The risk stack is concentrated: a company with $2.7B of current revenue and a $26B market cap is being asked to monetize science faster than the legacy vaccine business is fading.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
whether revenue can move above the $2.7B base
With fy2029 revenue only estimated at $3B, even modest progress matters. This is the number that tells you whether the reset is stabilizing.
risk
patent developments around mRNA vaccine technology
Recent legal headlines show the old COVID platform is still part of the story. If that overhang grows, sentiment gets hit first.
calendar
the next earnings release
This is where you look for evidence that cash is funding progress rather than just buying time.
trend
whether institutional selling finally stops
Three straight quarters of net selling is not fatal. It is a message. You want to see that message change before calling sentiment repaired.
Analyst rankings
earnings predictability
5 / 100
in human-speak, analysts do not expect a clean, steady earnings path here.
price stability
15 / 100
The stock has moved around a lot. This is a research name, not a sleep-well-at-night name.
balance sheet strength
B
Good enough to fund the pipeline, but not enough on its own to justify a premium multiple forever.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 102 buyers vs. 118 sellers in 3q2025. total institutional holdings: 50.6M shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$46
$140
$106
current price
$93
target midpoint · 12% from current · 3-5yr high: $170 (+60% · 13% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive